Nautilus Biotechnology, Inc.
NASDAQ:NAUTBiotechnology
+$0.05 today
- Market cap
- $309.51M
- Beta
- 0.75
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$0.45
Volume 4.55M
Average 0.40M
NAUT Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Nautilus Biotechnology, Inc.NASDAQ: NAUT
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $1.11M rose 6038.9% year over year, ahead of the +41.9% change in trailing-twelve-month financing cash flow. Sequentially, it rose 994.1% from the prior quarter. Over 3 fiscal years it compounded at -27.5% a year.
Context
- Financing cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +6038.9% holds above the trailing-twelve-month pace of +41.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 214K USD
- Year-over-year change
- -81.3%
- 4-year CAGR
- -84.0%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 214K | -81.3% |
| FY2024 | 2024-12-31 | 1.14M | +210.9% |
| FY2023 | 2023-12-31 | 368K | -34.5% |
| FY2022 | 2022-12-31 | 562K | -99.8% |
| FY2021 | 2021-12-31 | 327.45M | — |
Financing Cash Flow vs competitors
How NAUT compares with its peers on the latest reported figures
- NAUT's LTM Mar 2026 financing cash flow of $1.3M is the 9th largest of the 11 companies compared; the peer median is $46.38M.
- Its year-over-year change of +41.9% is the 5th highest of 11, against a peer median of +11.9%.
- Over three fiscal years its annual growth of -27.5% compares with a peer median of +48.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $212.95M | +1074.3% | +2184.5% | — | |
| LTM Mar 2026 | $172.89M | +451.1% | +557.7% | 243.2% | |
ZURAZura Bio Limited | LTM Mar 2026 | $127.78M | +11.1% | — | — |
| LTM Mar 2026 | $57.73M | +12.7% | +11.7% | 25658.2% | |
| LTM Mar 2026 | $50.66M | -51.5% | -16.6% | 179.5% | |
| LTM Mar 2026 | $42.1M | +263.6% | — | 60.8% | |
| LTM Mar 2026 | $38.07M | -61.2% | — | 1888.3% | |
| LTM Mar 2026 | $1.8M | -109.8% | — | 4.0% | |
| LTM Mar 2026 | $1.3M | +41.9% | -27.5% | — | |
| LTM Mar 2026 | $569K | -68.7% | +48.1% | 4.1% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $275K | +1118.5% | — | — |
| Peer median (excluding NAUT) | $46.38M | +11.9% | +48.1% | 179.5% | |
Competitors are the stored peer set for NAUT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (50.32M) | (57.92M) | (63.68M) | (70.78M) | (59M) |
| Depreciation & Amortization | 2.84M | 3.42M | 5.71M | 6.35M | 6.47M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.93M | 10.38M | 12.14M | 12.7M | 6.84M |
| Change in Working Capital | (22K) | (788K) | (3.22M) | (5.46M) | (3.58M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.26M | (561K) | 393K | (578K) | (69K) |
| Other Working Capital | (1.28M) | (227K) | (3.61M) | (4.88M) | (3.52M) |
| Other Non-Cash Items | 320K | (890K) | (2.66M) | (1.96M) | (1.42M) |
| Operating Cash Flow | (39.24M) | (45.81M) | (51.71M) | (59.15M) | (50.7M) |
| Capital Expenditures | (2.27M) | (2.32M) | (2.44M) | (2.12M) | (1.28M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (221.8M) | (186.59M) | (112.89M) | (86.28M) | (72.49M) |
| Sales of Investments | 85.1M | 163.18M | 71.6M | 155.41M | 108.99M |
| Other Investing Activities | 0 | 0 | 0 | (760K) | 0 |
| Investing Cash Flow | (138.96M) | (25.74M) | (43.74M) | 66.25M | 35.22M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | (7.96M) | 562K | 368K | 1.14M | 214K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 335.41M | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 327.45M | 562K | 368K | 1.14M | 214K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 149.24M | (70.98M) | (95.08M) | 8.25M | (15.26M) |
| Free Cash Flow | (41.51M) | (48.13M) | (54.15M) | (61.27M) | (51.97M) |
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
Intrinsic Alpha fair value
Locked
Current Price
$2.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.